相关实验视频

Updated: Jan 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在内分泌抵抗性转移性乳腺癌中的Palbociclib:现实世界的结果

Abdel-Hameed Ibrahim Mohamed Ebid¹, Yasmine Magdy Fahim Genina¹, Hesham Raafat Shawky Haffez^2,3

¹Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University, Cairo, Egypt.

Expert review of anticancer therapy

|September 16, 2025

概括

帕尔博西克利布改善了转移性乳腺癌患者的存活率,这些患者对内分泌治疗有抗性. 较低的Ki-67和中性与更好的结果相关,特别是在二次耐药性病例中.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

帕尔博西克利布是激素受体阳性,HER2阴性转移性乳腺癌的标准治疗方法.
内分泌耐药性是管理这种患者群体的一个重大挑战.

研究的目的:

评估palbociclib与内分泌治疗结合在内分泌耐药转移性乳腺癌中的疗效和耐受性.
确定无进展生存 (PFS) 和整体生存 (OS) 的预后因素.

主要方法:

140名患有内分泌抵抗性转移性乳腺癌的患者接受了palbociclib和内分泌治疗的回顾性队列研究.
分析影响PFS和OS的因素,包括Ki-67水平,中性质衰竭的严重程度和palbociclib治疗的持续时间.

主要成果:

低基-67水平和中度至重度的中性质与较长的PFS相关 (分别为p=0.004和p=0.026).
接受Palbociclib治疗≥12个月的患者的生存寿命更长 (p=0.0012).
二次抵抗组的生存时间比初级抵抗组的生存时间长 (p=0.0003).

结论:

低Ki-67和中度至重度的中性质预测了接受Palbociclib的内分泌耐药转移性乳腺癌患者的更好的生存结果.
帕尔博西克利布在这个具有挑战性的患者群体中表现出有效性,特定的生物标志物表明预后改善.

关键词:

循环素依赖的激酶抑制剂.它是HER2阴性的.转移性乳腺癌是发生转移的在Palbocicliblib中使用.内分泌耐药性的内分泌抵抗.有荷尔蒙受体阳性的人.总体存活率总体存活率没有进展的生存率.

更多相关视频

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...